| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Trevi Therapeutics, Inc. (TRVI) has 2 insiders with recent SEC Form 4 filings, including 8 buys and 0 sells. TRVI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 375.0K | $6.82M | - | |
| Other | 26.1K | $474.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 9, 2019 | Aperture Venture Partners Iv, L.P. | 10% Owner | Buy | 112,000 | $10.00 | $1,120,000.00 | +48.1% | |
| May 9, 2019 | Baskett Forest53 | 10% Owner | Buy | 2,500,000 | $10.00 | $25,000,000.00 | +51.3% | |
| May 9, 2019 | Barris Peter J | 10% Owner | Buy | 2,500,000 | $10.00 | $25,000,000.00 | +51.3% | |
| May 9, 2019 | Vanlent Anne | Director | Buy | 5,000 | $10.00 | $50,000.00 | +23.8% | |
| May 9, 2019 | Lundbeckfond Invest A/s | 10% Owner | Buy | 375,000 | $10.00 | $3,750,000.00 | +48.3% | |
| May 9, 2019 | Agger Mette Kirstine | Director | Buy | 375,000 | $10.00 | $3,750,000.00 | +48.3% |